heiDATA

Metrics

207,636 Downloads

Featured Dataverses

In order to use this feature you must have at least one published dataverse.

Publish Dataverse

Are you sure you want to publish your dataverse? Once you do so it must remain published.

Publish Dataverse

This dataverse cannot be published because the dataverse it is in has not been published.

Delete Dataverse

Are you sure you want to delete your dataverse? You cannot undelete this dataverse.

File Type: Document Publication Year: 2023

11 to 20 of 415 Results

Vardarli_Suppl Fig 14.pdf Nov 25, 2023 - Risk and incidence of endocrine immune related adverse effects under checkpoint inhibitor mono or combination therapy in solid tumors: a meta-analysis of randomized controlled trials [data] Adobe PDF - 80.9 KB - MD5: 62d291378b75e8e2a2f5a787bcfce5a4 Suppl. Fig. 14. Forest plot for cumulative meta-analysis for trials investigating adrenal insufficiency any grade under immune related checkpoint inhibitor therapy in solid tumors, n= 80 trials.
Vardarli_Suppl Fig 15.pdf Nov 25, 2023 - Risk and incidence of endocrine immune related adverse effects under checkpoint inhibitor mono or combination therapy in solid tumors: a meta-analysis of randomized controlled trials [data] Adobe PDF - 123.7 KB - MD5: e92bdfe54f4b36c5ebfe57df75bd5ca9 Suppl. Fig. 15. Forest plot for subgroups of ICI types trials investigating adrenal insufficiency grade 3-5 under immune related checkpoint inhibitor therapy in solid tumors, n= 80 trials.
Vardarli_Suppl Fig 16.pdf Nov 25, 2023 - Risk and incidence of endocrine immune related adverse effects under checkpoint inhibitor mono or combination therapy in solid tumors: a meta-analysis of randomized controlled trials [data] Adobe PDF - 80.0 KB - MD5: 7f9fed59c4ed1df3ea37f159e262e680 Suppl. Fig. 16. Forest plot for leave-one out meta-analysis for trials investigating insufficiency grade 3-5 under immune related checkpoint inhibitor therapy in solid tumors, n= 80 trials.
Vardarli_Suppl Fig 17.pdf Nov 25, 2023 - Risk and incidence of endocrine immune related adverse effects under checkpoint inhibitor mono or combination therapy in solid tumors: a meta-analysis of randomized controlled trials [data] Adobe PDF - 80.7 KB - MD5: 0d02b91d5d4afe3e1e0b55c74b735a25 Suppl. Fig. 17. Forest plot for cumulative meta-analysis for trials investigating adrenal insufficiency grade 3-5 under immune related checkpoint inhibitor therapy in solid tumors, n= 80 trials.
Vardarli_Suppl Fig 18.pdf Nov 25, 2023 - Risk and incidence of endocrine immune related adverse effects under checkpoint inhibitor mono or combination therapy in solid tumors: a meta-analysis of randomized controlled trials [data] Adobe PDF - 123.8 KB - MD5: e49c23bb1823756f90ba710a36a71d52 Suppl. Fig. 18. Forest plot for subgroups of ICI types trials investigating insulin-dependent diabetes mellitus any grade under immune related checkpoint inhibitor therapy in solid tumors, n= 80 trials.
Vardarli_Suppl Fig 19.pdf Nov 25, 2023 - Risk and incidence of endocrine immune related adverse effects under checkpoint inhibitor mono or combination therapy in solid tumors: a meta-analysis of randomized controlled trials [data] Adobe PDF - 80.6 KB - MD5: 7a5be4e2d1d4c1805b25946bfbb2a0e1 Suppl. Fig. 19. Forest plot for cumulative meta-analysis for trials investigating insulin-dependent diabetes mellitus any grade under immune related checkpoint inhibitor therapy in solid tumors, n= 80 trials.
Vardarli_Suppl Fig 1.pdf Nov 25, 2023 - Risk and incidence of endocrine immune related adverse effects under checkpoint inhibitor mono or combination therapy in solid tumors: a meta-analysis of randomized controlled trials [data] Adobe PDF - 1.2 MB - MD5: 715cdaed20ef88c2c0e8ca4261d863af Suppl. Fig. 1. Risk of bias summary for each included study, n= 80 trials.
Vardarli_Suppl Fig 20.pdf Nov 25, 2023 - Risk and incidence of endocrine immune related adverse effects under checkpoint inhibitor mono or combination therapy in solid tumors: a meta-analysis of randomized controlled trials [data] Adobe PDF - 123.6 KB - MD5: 6b83ff9a9da2c361ff0b4140ec06b958 Suppl. Fig. 20. Forest plot for subgroups of ICI types trials investigating insulin-dependent diabetes mellitus grade 3-5 under immune related checkpoint inhibitor therapy in solid tumors, n= 80 trials.
Vardarli_Suppl Fig 21.pdf Nov 25, 2023 - Risk and incidence of endocrine immune related adverse effects under checkpoint inhibitor mono or combination therapy in solid tumors: a meta-analysis of randomized controlled trials [data] Adobe PDF - 120.9 KB - MD5: 2a606fbb196c04b307bf9b66aa039486 Suppl. Fig. 21. Funnel plot for trials investigating hypothyroidism any grade under immune checkpoint inhibitor therapy in solid tumors, n= 80 trials.
Vardarli_Suppl Fig 22.pdf Nov 25, 2023 - Risk and incidence of endocrine immune related adverse effects under checkpoint inhibitor mono or combination therapy in solid tumors: a meta-analysis of randomized controlled trials [data] Adobe PDF - 72.2 KB - MD5: 0c3e0a9c165d70c9ce99c8dffde73b91 Suppl. Fig. 22. Galbraith plot for trials investigating hypothyroidism any under immune checkpoint inhibitor therapy in solid tumors, n= 80 trials.

Vardarli_Suppl Fig 14.pdf

Nov 25, 2023 - Risk and incidence of endocrine immune related adverse effects under checkpoint inhibitor mono or combination therapy in solid tumors: a meta-analysis of randomized controlled trials [data]

Adobe PDF - 80.9 KB -

Suppl. Fig. 14. Forest plot for cumulative meta-analysis for trials investigating adrenal insufficiency any grade under immune related checkpoint inhibitor therapy in solid tumors, n= 80 trials.

Vardarli_Suppl Fig 15.pdf

Adobe PDF - 123.7 KB -

Suppl. Fig. 15. Forest plot for subgroups of ICI types trials investigating adrenal insufficiency grade 3-5 under immune related checkpoint inhibitor therapy in solid tumors, n= 80 trials.

Vardarli_Suppl Fig 16.pdf

Adobe PDF - 80.0 KB -

Suppl. Fig. 16. Forest plot for leave-one out meta-analysis for trials investigating insufficiency grade 3-5 under immune related checkpoint inhibitor therapy in solid tumors, n= 80 trials.

Vardarli_Suppl Fig 17.pdf

Adobe PDF - 80.7 KB -

Suppl. Fig. 17. Forest plot for cumulative meta-analysis for trials investigating adrenal insufficiency grade 3-5 under immune related checkpoint inhibitor therapy in solid tumors, n= 80 trials.

Vardarli_Suppl Fig 18.pdf

Adobe PDF - 123.8 KB -

Suppl. Fig. 18. Forest plot for subgroups of ICI types trials investigating insulin-dependent diabetes mellitus any grade under immune related checkpoint inhibitor therapy in solid tumors, n= 80 trials.

Vardarli_Suppl Fig 19.pdf

Adobe PDF - 80.6 KB -

Suppl. Fig. 19. Forest plot for cumulative meta-analysis for trials investigating insulin-dependent diabetes mellitus any grade under immune related checkpoint inhibitor therapy in solid tumors, n= 80 trials.

Vardarli_Suppl Fig 1.pdf

Adobe PDF - 1.2 MB -

Suppl. Fig. 1. Risk of bias summary for each included study, n= 80 trials.

Vardarli_Suppl Fig 20.pdf

Adobe PDF - 123.6 KB -

Suppl. Fig. 20. Forest plot for subgroups of ICI types trials investigating insulin-dependent diabetes mellitus grade 3-5 under immune related checkpoint inhibitor therapy in solid tumors, n= 80 trials.

Vardarli_Suppl Fig 21.pdf

Adobe PDF - 120.9 KB -

Suppl. Fig. 21. Funnel plot for trials investigating hypothyroidism any grade under immune checkpoint inhibitor therapy in solid tumors, n= 80 trials.

Vardarli_Suppl Fig 22.pdf

Adobe PDF - 72.2 KB -

Suppl. Fig. 22. Galbraith plot for trials investigating hypothyroidism any under immune checkpoint inhibitor therapy in solid tumors, n= 80 trials.

Add Data

Share Dataverse

Link Dataverse

Reset Modifications